Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 6/20 | 0.45 |
| ▸ | BRD4 | O60885 | 5/20 | 0.44 |
| ▸ | PPIA | P62937 | 1/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13195028 | 0.94 | KCNH2 (0.47) | KCNH2BRD4PPIATLR7TLR8 | |
| SCHEMBL21920109 | 0.92 | BRD4 (0.44) | KCNH2BRD4PPIATLR7CYP11B1 | |
| SCHEMBL15469718 | 0.87 | TLR8 (0.46) | KCNH2BRD4PPIATLR7CYP11B1 | |
| SCHEMBL17123640 | 0.86 | TLR8 (0.42) | KCNH2BRD4TLR7TLR8 | |
| SCHEMBL13195038 | 0.85 | KCNH2 (0.57) | KCNH2TLR7ADORA1TLR8CYP2D6 | |
| SCHEMBL20219776 | 0.83 | KCNH2 (0.47) | KCNH2TLR7ADORA1TLR8CYP2D6 | |
| SCHEMBL15469762 | 0.81 | TLR7 (0.62) | TLR7ADORA1TLR8CYP2D6 | |
| SCHEMBL15469717 | 0.81 | BRD4 (0.42) | BRD4PPIACYP11B1CYP11B2ADORA3 | |
| SCHEMBL15470054 | 0.79 | KCNH2 (0.59) | KCNH2TLR7TLR8CYP2D6 | |
| SCHEMBL20219623 | 0.79 | KCNH2 (0.59) | KCNH2TLR7TLR8CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11541050-B2 | Pyrimidine derivatives for the treatment of viral infections | JANSSEN SCIENCES IRELAND UC (IE) | 2023-01-03 | — | — | US | disclosed |
| EP-3590928-B1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2021-06-09 | — | — | EP | disclosed |
| US-20210023082-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UC (IE) | 2021-01-28 | — | — | US | disclosed |
| US-10780089-B2 | Pyrimidine derivatives for the treatment of viral infections | JANSSEN SCIENCES IRELAND UC (IE) | 2020-09-22 | — | — | US | disclosed |
| EP-2903967-B3 | ACYLAMINOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND FURTHER DISEASES | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2020-04-15 | — | — | EP | disclosed |
| US-20200061059-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UC (IE) | 2020-02-27 | — | — | US | disclosed |
| US-10420767-B2 | Pyrimidine derivatives for the treatment of viral infections | JANSSEN SCIENCES IRELAND UC (IE) | 2019-09-24 | — | — | US | disclosed |
| US-10272085-B2 | Pyrimidine derivatives for the treatment of viral infections | JANSSEN SCIENCES IRELAND UC (IE) | 2019-04-30 | — | — | US | disclosed |
| US-20180207155-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UC (IE) | 2018-07-26 | — | — | US | disclosed |
| US-20180207155-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UC (IE) | 2018-07-26 | — | — | US | disclosed |
| US-9790191-B2 | Substituted acylaminopyrimidines as inducers of alpha interferon production | JANSSEN SCIENCES IRELAND UC (IE) | 2017-10-17 | — | — | US | disclosed |
| US-9790191-B2 | Substituted acylaminopyrimidines as inducers of alpha interferon production | JANSSEN SCIENCES IRELAND UC (IE) | 2017-10-17 | — | — | US | disclosed |
| US-20170239245-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UC (IE) | 2017-08-24 | — | — | US | disclosed |
| US-20170239245-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UC (IE) | 2017-08-24 | — | — | US | disclosed |
| US-9422250-B2 | Pyrimidine derivatives for the treatment of viral infections | JANSSEN SCIENCES IRELAND UC (IE) | 2016-08-23 | — | — | US | disclosed |
| US-9422250-B2 | Pyrimidine derivatives for the treatment of viral infections | JANSSEN SCIENCES IRELAND UC (IE) | 2016-08-23 | — | — | US | disclosed |
| US-20150274676-A1 | ACYLAMINOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND FURTHER DISEASES | JANSSEN SCIENCES IRELAND UC (IE) | 2015-10-01 | — | — | US | disclosed |
| US-20150274676-A1 | ACYLAMINOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND FURTHER DISEASES | JANSSEN SCIENCES IRELAND UC (IE) | 2015-10-01 | — | — | US | disclosed |
| US-20140045849-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UC (IE) | 2014-02-13 | — | — | US | disclosed |
| US-20140045849-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UC (IE) | 2014-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10780089-B2 | Pyrimidine derivatives for the treatment of viral infections | TYMP, UMPS, HPRT1 | KCNH2 4679/4885BRD4 1243/4885PPIA 1012/4885 |
| US-20150274676-A1 | ACYLAMINOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND FURTHER DISEASES | DPYD, TYMP, ENTPD5 | KCNH2 3209/4885BRD4 322/4885PPIA 1187/4885 |
| US-20200061059-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | TYMP, UMPS, HPRT1 | KCNH2 4679/4885BRD4 1243/4885PPIA 1012/4885 |
| US-10420767-B2 | Pyrimidine derivatives for the treatment of viral infections | TYMP, UMPS, HPRT1 | KCNH2 4679/4885BRD4 1243/4885PPIA 1012/4885 |
| US-20140045849-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | TYMP, UMPS, HPRT1 | KCNH2 4679/4885BRD4 1243/4885PPIA 1012/4885 |
| US-10272085-B2 | Pyrimidine derivatives for the treatment of viral infections | TYMP, UMPS, HPRT1 | KCNH2 4679/4885BRD4 1243/4885PPIA 1012/4885 |
| US-11541050-B2 | Pyrimidine derivatives for the treatment of viral infections | TYMP, UMPS, HPRT1 | KCNH2 4679/4885BRD4 1243/4885PPIA 1012/4885 |
| US-20210023082-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | TYMP, UMPS, HPRT1 | KCNH2 4679/4885BRD4 1243/4885PPIA 1012/4885 |
| US-20180207155-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | TYMP, UMPS, HPRT1 | KCNH2 4679/4885BRD4 1243/4885PPIA 1012/4885 |
| US-20170239245-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | TYMP, UMPS, HPRT1 | KCNH2 4679/4885BRD4 1243/4885PPIA 1012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.